| Literature DB >> 27799882 |
Satoshi Hiyama1, Hideki Iijima2, Syoichiro Kawai2, Akira Mukai3, Eri Shiraishi3, Shuko Iwatani2, Toshio Yamaguchi2, Manabu Araki2, Yoshito Hayashi2, Shinichiro Shinzaki2, Tsunekazu Mizushima4, Masahiko Tsujii5, Tetsuo Takehara2.
Abstract
BACKGROUND/AIMS: Peyer's patches (PPs) are aggregates of lymphoid follicles that are mainly located in the distal ileum; they play a major role in mucosal immunity. We recently reported that patients with ulcerative colitis (UC) have alterations in PPs that can be detected using narrow-band imaging with magnifying endoscopy (NBI-ME). However, the usefulness of NBI-ME in UC treatment as a whole is still unknown.Entities:
Keywords: Colitis, ulcerative; Narrow-band imaging; Peyer's patch
Year: 2016 PMID: 27799882 PMCID: PMC5083260 DOI: 10.5217/ir.2016.14.4.314
Source DB: PubMed Journal: Intest Res ISSN: 1598-9100
Patient Characteristics
| Variable | Total (n=67) | L-type (n=35) | H-type (n=32) | P-value |
|---|---|---|---|---|
| Age at colonoscopy (yr) | 44.2 (17–75) | 45.7 (21–68) | 42.5 (17–75) | 0.3200 |
| Age at diagnosis (yr) | 34.5 (14–71) | 36.4 (16–68) | 32.5 (14–71) | 0.0800 |
| Female/male | 28/39 | 15/20 | 13/19 | 0.8500 |
| Disease duration (yr) | 9.5 (0–36) | 9.3 (0–28) | 9.8 (0–36) | 0.8000 |
| Disease extent (pancolitis/left-sided colitis/proctitis) | 29/22/16 | 13/13/9 | 16/9/7 | 0.3900 |
| Partial Mayo score (≤2/≥3) | 52/15 | 29/6 | 23/9 | 0.2800 |
| Mayo endoscopic subscore (0/1/2/3) | 23/30/10/4 | 10/17/7/1 | 13/13/3/3 | 0.6500 |
| Inflammation in terminal ileum (present/absent) | 4/63 | 1/34 | 3/29 | 0.2600 |
| Reddish peri-appendiceal mucosa (present/absent) | 14/53 | 2/33 | 12/20 | 0.0014 |
| Concomitant medication | ||||
| Aminosalicylates | 54 (81.0) | 28 (80.0) | 26 (81.3) | 0.9000 |
| Oral corticosteroids | 6 (9.0) | 2 (5.7) | 4 (12.5) | 0.3300 |
| Immunomodulator | 8 (11.9) | 3 (8.6) | 5 (15.6) | 0.3700 |
| Anti-TNF therapy | 1 (1.5) | 0 | 1 (3.1) | 0.2900 |
| No medication | 13 (19.4) | 7 (20.0) | 6 (18.8) | 0.9000 |
Values are presented as average (range) or number (%).
L-type, low-type; H-type, high-type; TNF, tumor necrosis factor.
Fig. 1Narrow-band imaging with magnifying endoscopy allowed us to clearly observe Peyer's patches: aggregates of multiple domes (d) surrounded by villi (v) with semi-circular vessels.
Fig. 2(A) Scatterplot of the villi index against Mayo endoscopic subscore at the colonoscopy. No correlation was seen between the villi index and the Mayo endoscopic subscore. Bars represent the mean. Representative images of L-type (B) and H-type (C) Peyer's patches (PPs) (black arrows, irregular formation; white arrow, hyperemia; arrowheads, altered vascular network pattern). (D) Evaluation of PPs by narrow-band imaging with magnifying endoscopy in UC patients using the "villi index." Thirty-five patients showed L-type PPs (villi index, 0 or 1), while 32 showed H-type PPs (villi index, 2 or 3). (E) A representative image of the reddish peri-appendiceal mucosa in patients with UC. H-type, high-type; L-type, low-type.
Characteristics of Patients in Clinical Remission
| Variable | L-type (n=29) | H-type (n=23) | |
|---|---|---|---|
| Age at colonoscopy (<40/≥40 yr) | 11/18 | 13/10 | 0.140 |
| Age at diagnosis (<40/≥40 yr) | 17/12 | 16/7 | 0.300 |
| Female/male | 13/16 | 13/10 | 0.290 |
| Disease duration (<10/≥10 yr) | 17/12 | 13/10 | 0.550 |
| Extent of involvement (pancolitis/left-sided colitis & proctitis) | 9/20 | 9/14 | 0.380 |
| Mayo endoscopic subscore (0/1 or 2) | 10/19 | 13/10 | 0.095 |
| Inflammation in terminal ileum (present/absent) | 0/29 | 3/20 | 0.080 |
| Reddish peri-appendiceal mucosa (present/absent) | 2/27 | 8/15 | 0.014 |
| Oral steroid use within 1 year (yes/no) | 4/25 | 4/19 | 0.510 |
| Use of aminosalicylate (yes/no) | 23/6 | 18/5 | 0.930 |
| Use of immunomodulator/anti-TNF antibody/tacrolimus (yes/no) | 3/26 | 0/23 | 0.170 |
L-type, low-type; H-type, high-type; TNF, tumor necrosis factor.
Fig. 3Results of the Kaplan-Meier survival analysis showing the cumulative proportion of patients who experienced clinical recurrence based on Peyer's patch imaging using narrow-band imaging with magnifying endoscopy (A) and Mayo endoscopic subscore (B). H-type, high-type; L-type, low-type.
Predictors of Clinical Recurrence according to Univariate and Multivariate Analyses
| Baseline factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age (<40 yr) | 0.0090 | 3.00 (1.30–7.30) | 0.3600 | 1.70 (0.58–6.00) |
| Age at diagnosis (<40 yr) | 0.0180 | 2.90 (1.20–8.20) | 0.3500 | 1.90 (0.47–7.10) |
| Female sex | 0.4700 | 0.74 (0.32–1.70) | - | - |
| Disease duration (<10 yr) | 0.2900 | 1.60 (0.70–3.70) | - | - |
| Extent of involvement (pancolitis) | 0.6900 | 1.20 (0.50–2.60) | - | - |
| Mayo endoscopic subscore (0) | 0.7900 | 0.90 (0.39–2.00) | - | - |
| Inflammation in terminal ileum (present) | 0.2200 | 2.80 (0.45–9.70) | - | - |
| Oral steroid use within 1 year (yes) | 0.0230 | 3.30 (1.20–8.00) | 0.1100 | 2.40 (0.81–6.10) |
| Use of aminosalicylate (yes) | 0.1900 | 2.00 (0.73–6.80) | - | - |
| Use of immunomodulator/anti-TNF antibody/tacrolimus (yes) | 0.4600 | 0.51 (0.028–2.400) | - | - |
| Irregularity of villi (H-type) | 0.0052 | 3.10 (1.40–7.50) | 0.0047 | 3.30 (1.40–8.20) |
HR, hazard ratio; TNF, tumor necrosis factor; H-type, high-type.